UBS Maintains Buy on Minimed Group, Raises Price Target to $28
Benzinga Newsdesk 2 months ago
NewsPrice TargetAnalyst Ratings
UBS analyst Patrick Wood maintains Minimed Group (NASDAQ:MMED) with a Buy and raises the price target from $25 to $28.
UBS analyst Patrick Wood maintains Minimed Group (NASDAQ:MMED) with a Buy and raises the price target from $25 to $28.